DE68911693D1 - Pharmazeutisches mittel für behandlung von menschlichem krebs und verfahren zu seiner herstellung. - Google Patents

Pharmazeutisches mittel für behandlung von menschlichem krebs und verfahren zu seiner herstellung.

Info

Publication number
DE68911693D1
DE68911693D1 DE89906213T DE68911693T DE68911693D1 DE 68911693 D1 DE68911693 D1 DE 68911693D1 DE 89906213 T DE89906213 T DE 89906213T DE 68911693 T DE68911693 T DE 68911693T DE 68911693 D1 DE68911693 D1 DE 68911693D1
Authority
DE
Germany
Prior art keywords
subjected
production
pharmaceutical agent
human cancer
treating human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE89906213T
Other languages
English (en)
Other versions
DE68911693T2 (de
Inventor
Kuslima Shogen
Stanislaw Mikulski
Wojciech Ardelt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tamir Biotechnology Inc
Original Assignee
Alfacell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfacell Corp filed Critical Alfacell Corp
Publication of DE68911693D1 publication Critical patent/DE68911693D1/de
Application granted granted Critical
Publication of DE68911693T2 publication Critical patent/DE68911693T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE89906213T 1988-04-06 1989-03-31 Pharmazeutisches mittel für behandlung von menschlichem krebs und verfahren zu seiner herstellung. Expired - Lifetime DE68911693T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/178,118 US4882421A (en) 1982-09-23 1988-04-06 Pharmaceutical for treating tumors and method for making it
PCT/US1989/001357 WO1989009606A1 (en) 1982-09-23 1989-03-31 Pharmaceutical for treating tumors in humans and method for making it

Publications (2)

Publication Number Publication Date
DE68911693D1 true DE68911693D1 (de) 1994-02-03
DE68911693T2 DE68911693T2 (de) 1994-05-11

Family

ID=22651277

Family Applications (1)

Application Number Title Priority Date Filing Date
DE89906213T Expired - Lifetime DE68911693T2 (de) 1988-04-06 1989-03-31 Pharmazeutisches mittel für behandlung von menschlichem krebs und verfahren zu seiner herstellung.

Country Status (6)

Country Link
US (1) US4882421A (de)
EP (1) EP0440633B1 (de)
JP (1) JPH03503530A (de)
AT (1) ATE98869T1 (de)
DE (1) DE68911693T2 (de)
WO (1) WO1989009606A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540925A (en) * 1988-04-06 1996-07-30 Alfacell Corporation Compositions comprising ONCONASE (TM) and STELAZINE (TM) or TAMOXIFEN (TM)
US5559212A (en) * 1988-04-06 1996-09-24 Alfacell Corporation Frog embryo and egg-derived tumor cell anti-proliferation protein
US5728805A (en) * 1988-04-06 1998-03-17 Alfacell Corp. Pharmaceuticals and method for making them
US5529775A (en) * 1988-04-06 1996-06-25 Alfacell Corporation Compositions comprising ONCONASE(™) and cisplatin, melphalan, or doxorubicin HCl
US5595734A (en) * 1988-04-06 1997-01-21 Alfacell Corporation Compositions comprising ONCONASE (tm) and lovastatin
DE69006741T2 (de) * 1989-11-13 1994-06-01 Alfacell Corp Reines protein und bioaktive pharmazeutische produkte.
HU221407B1 (hu) * 1997-03-28 2002-09-28 Gyula Magvasi Ektodermális eredetû szövetekben fellépõ tumoros burjánzást gátló hatóanyag és készítmény, valamint eljárás elõállításukra
US6239257B1 (en) * 1998-12-30 2001-05-29 Alfacell Corporation Family of proteins belonging to the pancreatic ribonuclease a superfamily
BRPI0716597A2 (pt) * 2006-09-08 2013-10-08 Wyeth Corp Método para o isolamento de um produto; produto preparado pelo método; método para o isolamento de um anticorpo; método para reduzir a turvação de um eluído compreendendo em produto; e método para reduzir a turvação e impurezas de um eluído compreendendo um produto
US9919034B2 (en) 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
US10835598B2 (en) 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
AU2016277827B2 (en) 2015-06-15 2021-04-29 Orgenesis Inc. Pharmaceuticals for treatment of viral infections of the eye

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2356426A1 (fr) * 1976-06-29 1978-01-27 Truffier Jean Claude Fraction ovomucoide du blanc de l'oeuf de caille, ayant des proprietes antiproteasiques
FR2489690A1 (fr) * 1979-05-07 1982-03-12 Coturnix Procede d'obtention de la fraction ovomucoide et d'un extrait d'ovomucoide de l'oeuf de caille, produits ainsi obtenus et leur application a titre de medicament

Also Published As

Publication number Publication date
EP0440633A1 (de) 1991-08-14
WO1989009606A1 (en) 1989-10-19
EP0440633B1 (de) 1993-12-22
JPH03503530A (ja) 1991-08-08
US4882421A (en) 1989-11-21
ATE98869T1 (de) 1994-01-15
DE68911693T2 (de) 1994-05-11

Similar Documents

Publication Publication Date Title
Lepage et al. Purification and characterization of the sea urchin embryo hatching enzyme
Evers et al. Microwave-stimulated antigen retrieval is pH and temperature dependent.
DE68911693D1 (de) Pharmazeutisches mittel für behandlung von menschlichem krebs und verfahren zu seiner herstellung.
PT87394A (pt) Process for plant tissue transformation
DE68929077D1 (de) Transplantieren von genetisch modifizierten zellen zur behandlung von krankheiten des zentralen nervensystems
ATE96033T1 (de) Mittel zur behandlung von arthrosen.
ES8203218A1 (es) Procedimiento para la preparacion de nuevos transplantes de organos
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
Samejima et al. Degradation of myofibrillar protein components during postmortem aging of chicken muscle
ATE203997T1 (de) Antiwachstumwirksame proteine aus oozyten von rana pipiens
BR8202494A (pt) Processo para preparar tecido natural fixo bem como tecido natural fixo valvula cardiaca fixa de suino e tecido fixo de pericardio de bovino adequados para implante
JPH11501055A (ja) 真珠層を含む組成物の新規な使用
DE3684868D1 (de) Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
NO912621D0 (no) Fremgangsmaate for innfoering av dna i animalske celler.
Ingalls et al. Acquired chromosomal anomalies induced in mice by injection of a teratogen in pregnancy
EP0187361A3 (de) Präparate mit verzögerter Wirkung, Verfahren zu deren Herstellung sowie entprechende Mittel zur Human- bzw. veterinärmedizinischen Anwendung
ATE124706T1 (de) Verfahren zur isolierung von basalmembranproteinen aus menschlichen und tierischen geweben.
ATE30114T1 (de) Mittel zur pflege oder behandlung der menschlichen haut.
AT298664B (de) Verfahren zur Herstellung von Leitschienen aus menschlichen oder tierischen Geweben zur Wiederherstellung beschädigter oder zerstörter spezifischer Gewebsteile im menschlichen und tierischen Körper
Slack The metabolism of sulphated polysaccharides in limb atrophy in the rat
Tu et al. Comparison of Naja naja siamensis and Naja naja atra venoms
JPS62116519A (ja) 人胎盤抽出細胞代謝活性化物質
Yang et al. The effect of heparin on growth of mammalian cells in vitro
GB2003887A (en) Isolation of peptides from urine
Fabiny Effects of versene and β‐2‐thienylalanine on the developing down feather

Legal Events

Date Code Title Description
8364 No opposition during term of opposition